MedTrace Logo

Drug-Drug Interaction Study of Atumelnant in Healthy Participants

NCT07570082 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2026-05-06

No results posted yet for this study

Summary

This study aims to evaluate the impact of strong CYP3A4 induction on the pharmacokinetics (PK) of atumelnant, as well as the effect of atumelnant on CYP3A4, P-gp, and MATE1/2-K substrates in healthy participants.

Conditions

  • Healthy Volunteers

Interventions

DRUG

Atumelnant

Atumelnant, tablets

DRUG

Carbamazepine

CYP3A4 inducer

DRUG

Midazolam

CYP3A4 substrate

DRUG

Digoxin

P-gp substrate

DRUG

Metformin

MATE1/2-K substrate

Sponsors & Collaborators

  • Crinetics Pharmaceuticals Inc.

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
19 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-06
Primary Completion
2026-12-31
Completion
2026-12-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07570082 on ClinicalTrials.gov